Onconetix, Inc. Reports Shareholder Nomination Event

Ticker: ONCO · Form: 8-K · Filed: 2025-10-29T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-action

TL;DR

Onconetix (ONCO) filed an 8-K for shareholder nominations on Oct 23rd.

AI Summary

Onconetix, Inc. filed an 8-K on October 29, 2025, reporting a shareholder nomination event that occurred on October 23, 2025. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.

Why It Matters

This filing indicates potential changes in the company's board of directors or strategic direction due to shareholder nominations.

Risk Assessment

Risk Level: low — The filing is procedural and relates to standard corporate governance, not immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a shareholder nomination event that occurred on October 23, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on October 29, 2025.

What were the previous names of Onconetix, Inc.?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.

Where are Onconetix, Inc.'s principal executive offices located?

Onconetix, Inc.'s principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 12.7 · Accepted 2025-10-29 12:17:30

Key Financial Figures

Filing Documents

08. Shareholder Director Nominations

Item 5.08. Shareholder Director Nominations. As disclosed in the Preliminary Proxy Statement on Schedule 14A (the "Proxy Statement") filed by Onconetix, Inc. (the "Company") with the Securities and Exchange Commission (the "SEC") on October 29, 2025, the Company's Board of Directors determined on October 23, 2025 that the 2025 annual meeting of stockholders (the "Annual Meeting") shall be held at 10:00 a.m. Eastern Time on December 5, 2025 at the offices of Ellenoff Grossman & Schole LLP, 1345 6th Ave, New York, NY 10105. Because the Company is holding the 2025 Annual Meeting more than 60 days subsequent to the anniversary of last year's Annual Meeting of Shareholders, as provided in Rule 14a-8 of the Securities Exchange Act of 1934, as amended (Rule 14a-8), the Company is hereby providing the date by which shareholder proposals must be received by the Company to be included in the proxy statement for the 2025 Annual Meeting. Deadline for Rule 14a-8 Stockholder Proposals To be considered for inclusion in proxy materials for the 2025 Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 and intended to be presented at the Annual Meeting must be received by the Company at 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio no later than the close of business on November 10, 2025. Any proposal received after such date will be considered untimely. All Rule 14a-8 proposals must be in compliance with applicable laws and regulations in order to be considered for inclusion in the Company's proxy materials for the 2025 Annual Meeting. The public announcement of an adjournment or postponement of the date of the Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8. Advance Notice Deadline for Director Nominations To be considered for inclusion in proxy materials for the 2025 Annual Meeting to bring nominations for directors, any such nominations must be received by the Company at

View on Read The Filing